Background: Combining PD-1 blockade with chemotherapy has widely used in first line
treatment of metastatic esophageal squamous cell carcinoma (ESCC). However, their …

e16008 Background: Although preoperative chemoradiotherapy is the standard of care for
patients with resectable locally advanced esophageal cancer, prognosis still remains poor …

Background Immunotherapy (Programmed cell death 1 blockade) has entered the ranks of
advanced esophageal cancer first-line treatment; however, little is known about the efficacy …

Background Compared with neoadjuvant chemotherapy, concurrent radiotherapy can
significantly increase pCR rate and improve overall survival of Locally Advanced ESCC …

Background Although neoadjuvant chemotherapy has been recommended for resectable
ESCC patients, the 5-year overall survival rate was less than 50%. Immune checkpoint …

Background Neoadjuvant programmed death receptor-1 (PD-1) inhibitor combined with
chemotherapy has been reported to improve the pathological response of locally advanced …

Background The standard neoadjuvant treatments in patients with esophageal squamous
cell carcinoma (ESCC) still have either poor safety or efficacy. Better therapies are needed …

Background Although preoperative chemoradiotherapy is the standard of care for patients
(pts) with resectable locally advanced esophageal cancer, ESCC still has a dismal …

e16091 Background: Many phase III clinical trials (Keynote 590, Orient 15, etc) have all
proved the role of immunotherapy combined with chemotherapy in the treatment of …

Background To investigate the safety and feasibility of combining neoadjuvant sintilimab
(Innovent Biologics, Suzhou, China) and chemotherapy for locally advanced esophageal …